

International



5–7 November 2021



SAVE  
THE DATE

Welcome

Agenda

This meeting is co-sponsored by:



Amgen (Europe) GmbH  
6343 Rotkreuz  
Switzerland  
[www.amgen.com](http://www.amgen.com)



Autolus, The MediaWorks  
191 Wood Lane, White City  
London, W12 7FP UK  
[www.autolus.com](http://www.autolus.com)

# WELCOME

[Agenda](#)

You are cordially invited to attend the 5th International ALL Assembly, an educational event dedicated to supporting the care of children and adults with acute lymphoblastic leukaemia (ALL) through sharing of expert knowledge, perspectives and experience.

With an agenda developed by a panel of international experts, this engaging forum will provide an important opportunity to discuss the latest scientific and clinical data, exploring their implications for patient care, debate current clinical questions and explore challenging patient cases.

The meeting will take place online via an interactive virtual platform, allowing delegates to view live presentations, participate in e-learning exercises and access post-meeting educational content.

## STEERING COMMITTEE



**Renato Bassan**  
Italy



**Nicolas Boissel**  
France



**Adele Fielding**  
UK



**Nicola Gökbuget**  
Germany



**Franco Locatelli**  
Italy



**Christina Peters**  
Austria



**Josep Ribera**  
Spain

# AGENDA

Welcome

## DAY 1: FRIDAY 5 NOVEMBER, 17.00–20.10 CET

### Optimising current approaches for treating ALL

T-cell ALL

Management of measurable residual disease (MRD) in B-ALL

Philadelphia chromosome-positive ALL

Panel discussion and Q&A

### Interactive case-study workshops

Delegates to select one per rotation

#### FIRST ROTATION

1. Secondary malignancy following treatment for ALL
2. Safety profile of CAR-T cells
3. Safety profile of BiTE® therapy

#### SECOND ROTATION

4. Safety profile of antibody–drug conjugates
5. Prevention and management of infectious complications in patients given B-cell-depleting immuno-oncology therapy
6. Management of ALL in patients with Down's syndrome

## DAY 2: SATURDAY 6 NOVEMBER, 09.00–12.15 CET

### Optimising current approaches for haematopoietic stem cell transplantation (HSCT)

Reviewing the indications for allogeneic HSCT

Post-HSCT management of ALL

Panel discussion and Q&A

### Interactive debate

Does allogeneic HSCT still have a role in patients who have received CAR-T cells?

Panel discussion and Q&A

### Management of relapsed/refractory B-ALL

Treating late relapse of paediatric ALL

Small-molecule inhibitors

BiTE® immuno-oncology therapy and antibody–drug conjugates

CAR-T cells

Panel discussion and Q&A

## DAY 3: SUNDAY 7 NOVEMBER, 09.00–12.15 CET

### New frontiers in the management of ALL

Advances in MRD evaluation

Mechanisms of resistance to immuno-oncology therapy

Practical applications of new data on genetic ALL subtypes

Immunotherapy of T-ALL: opportunities and hurdles

Panel discussion and Q&A

### Interactive debate

Should we avoid CD19-directed immuno-oncology therapy in patients hoping to receive CD19-directed CAR-T cells?

Panel discussion and Q&A

### Special-interest workshop (delegates to select one)

1. Optimal use of asparaginase (paediatric and adult perspectives)
2. Management of toxicity associated with methotrexate
3. Supportive care in patients with ALL (paediatric and adult perspectives)
4. Pregnancy in patients with ALL
5. Predisposition to ALL
6. Diagnostic procedures in ALL: current standards and future options
7. Novel technologies with future applications for ALL

### Closing ceremony and recap